New data set Herceptin on a subcutaneous, self-administration course
This article was originally published in Scrip
Executive Summary
Phase III data supporting Roche's attempts to prolong the life of its pioneering breast cancer treatment Herceptin (trastuzumab) by showing that a subcutaneous version that takes only five minutes to administer is just as good as the current intravenous product have been presented at a breast cancer conference in Vienna.